Troglitazone
- Generic Name
- Troglitazone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H27NO5S
- CAS Number
- 97322-87-7
- Unique Ingredient Identifier
- I66ZZ0ZN0E
- Background
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
- Indication
For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.
- Associated Conditions
- -
- Associated Therapies
- -
TART - Troglitazone Atherosclerosis Regression Trial
Phase 2
Completed
- Conditions
- AtherosclerosisDiabetes Mellitus
- First Posted Date
- 2005-06-30
- Last Posted Date
- 2009-12-11
- Lead Sponsor
- Parke-Davis
- Target Recruit Count
- 288
- Registration Number
- NCT00116545
- Locations
- 🇺🇸
Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine, Los Angeles, California, United States
Troglitazone in Treating Patients With Liposarcoma
- First Posted Date
- 2004-08-12
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 85
- Registration Number
- NCT00003058
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath